Could a common gut drug clear the way for life-saving endoscopy?
NCT ID NCT07749300
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial tests whether giving trimebutine maleate before an urgent endoscopy can clear blood and clots from the stomach, giving doctors a better view of the bleeding source. About 100 adults with acute upper gastrointestinal bleeding will receive either the drug or a placebo before their procedure. The study measures how clearly the stomach lining can be seen and whether the bleeding source is more easily identified.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Trimebutine Maleate
- What this could lead to
- If effective, this could improve the accuracy and speed of emergency endoscopy for upper GI bleeding, potentially reducing the need for repeat procedures.
- What could go wrong
- This is a mid-stage trial with a modest number of participants, so results may not be definitive. The drug may not significantly improve visualization, and there is a small risk of side effects or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years. * Clinical evidence of AUGIB: Hematemesis, coffee-ground vomiting or melena. * Planned urgent upper gastrointestinal endoscopy within 24 hours. Exclusion Criteria: * Known gastric outlet obstruction. * Previous gastric surgery. * Pregnancy or lactation. * Allergy to Trimebutine Maleate. * Chronic use of prokinetic medications.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute upper gastrointestinal bleeding are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why do some ICU patients bleed in the gut? researchers map the risk
- Does the clock matter? trial tests endoscopy timing for cirrhosis bleeding
- Medical glue vs. internal bleeding: a new hope?
- Stomach bleeding linked to kidney damage: new study to track who is at risk
- Chatbot boosts doctor trust in AI for bleeding emergencies?
- Clip or coil? new study tests best way to stop stomach bleeding